drug

Lorazepam 2 MG/ML

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Temple University Collaborative on Community Inclusion
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder
NCT06093451Phase 4Unknown

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Temple University Collaborative on Community Inclusion
company
trial
Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder
PHASE4
trial
indication
Schizophrenia
indication
Schizo Affective Disorder
indication
Schizophrenia Agitation
indication
Dexmedetomidine
indication